Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
-
ACADEMIA Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
-
BUSINESS Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
-
REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
-
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
-
BUSINESS Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
-
ORGANIZATION JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
-
BUSINESS Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
-
BUSINESS AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
-
BUSINESS Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
-
REGULATORY MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
-
BUSINESS Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
-
BUSINESS Weber to Become CEO of Takeda in April
March 4, 2015
-
REGULATORY Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
-
BUSINESS Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…